First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension (Q24186647)

2

0 references

Wen Lu Tang

3

0 references

Lu Wei Pang

4

0 references

Gan Mi Wang

5

0 references

Gavin WK Wong

6

0 references

James M Wright

Cochrane Database of Systematic Reviews

7

0 references

publication date

11 January 2015

0 references

published in

0 references

cites work

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Pr

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Heart failure in ALLHAT: did blood pressure medication at study entry influence outcome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLH

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Pharmacogenetic association of NOS3 variants with cardiovascular disease in patients with hypertension: the GenHAT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Myocardial perfusion during long-term angiotensin-converting enzyme inhibition or beta-blockade in patients with essential hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized,

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Effects of doxazosin and irbesartan on blood pressure and metabolic control in patients with type 2 diabetes and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Effects of enalapril/lercanidipine combination on some emerging biomarkers in cardiovascular risk stratification in hypertensive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study e

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Effect of telmisartan on paroxysmal atrial fibrillation recurrence in hypertensive patients with normal or increased left atrial size

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Effect of single-drug therapy on reduction of left atrial size in mild to moderate hypertension: comparison of six antihypertensive agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive impairment: results of a pilot randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Effect of antihypertensive treatment on retinal microvascular changes in hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Cardiovascular morbidity and mortality in hypertensive patients with lower versus higher risk: a LIFE substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Pulse pressure, left ventricular function and cardiovascular events during antihypertensive treatment (the LIFE study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Serial evaluation of electrocardiographic left ventricular hypertrophy for prediction of risk in hypertensive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Greater regression of electrocardiographic left ventricular hypertrophy during hydrochlorothiazide therapy in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Comparison of actions of irbesartan versus atenolol on cardiac repolarization in hypertensive left ventricular hypertrophy: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Long-term effects of irbesartan and atenolol on the renin-angiotensin-aldosterone system in human primary hypertension: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Comparison of effects of quinapril and metoprolol on glycaemic control, serum lipids, blood pressure, albuminuria and quality of life in non-insulin-dependent diabetes mellitus patients with hypertension. Swedish Quinapril Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

One-year renal and cardiac effects of bisoprolol versus losartan in recently diagnosed hypertensive patients: a randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

A comparison of the effect of ramipril, felodipine and placebo on glomerular filtration rate, albuminuria, blood pressure and vasoactive hormones in chronic glomerulonephritis. A randomized, prospective, double-blind, placebo-controlled study over t

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Preventing microalbuminuria in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Effects of a beta-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Effect of irbesartan versus atenolol on left ventricular mass and voltage: results of the CardioVascular Irbesartan Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: effects on albumin excretion, endothelial function and inflammation in a double-blind, random

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Antihypertensive Effect and Tolerability of Perindopril in Indian Hypertensive and Type 2 Diabetic Patients: 1-Year Randomised, Double-Blind, Parallel Study vs Atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Effects of amlodipine and lisinopril on intima-media thickness in previously untreated, elderly hypertensive patients (the ELVERA trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Standards of medical care in diabetes--2013

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Grading quality of evidence and strength of recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Calcium channel blockers versus other classes of drugs for hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

The prevention of type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Optimal blood pressure control and antihypertensive regimens in hypertensive renal disease: the potential of exploring the mechanisms of response variability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Angiotensin receptor blockers as anti-hypertensive treatment for patients with diabetes mellitus: meta-analysis of controlled double-blind randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Antihypertensive agents for preventing diabetic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Beta-blockers for hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

First-line drugs for hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Candesartan- and Atenolol-Based Treatments Induce Different Patterns of Carotid Artery and Left Ventricular Remodeling in Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Effects of nitrendipine and enalapril on left ventricular mass in patients with non-insulin-dependent diabetes mellitus and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

7 January 2021

A double-blind comparison of the effects of carvedilol and captopril on serum lipid concentrations in patients with mild to moderate essential hypertension and dyslipidaemia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

7 January 2021

Risk factors for coronary heart disease mortality among persons with diabetes.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

7 January 2021

Antihypertensive therapy in type 2 diabetes: implications of the appropriate blood pressure control in diabetes (ABCD) trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

7 January 2021

Elevated blood pressure among U.S. adults with diabetes, 1988-1994

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

7 January 2021

Long-term renal preservation in essential hypertension. Angiotensin converting enzyme inhibition is superior to beta-blockade

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

7 January 2021

Differential effects of angiotensin converting enzyme inhibition and diuretic therapy on reductions in ambulatory blood pressure, left ventricular mass, and vascular hypertrophy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

7 January 2021

Large and small artery endothelial function in patients with essential hypertension--effect of ACE inhibition and beta-blockade

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

7 January 2021

Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

7 January 2021

The influence of antihypertensive therapy on the structural arteriolar changes in essential hypertension: different effects of enalapril and hydrochlorothiazide

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

7 January 2021

Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

7 January 2021

Changes in aortic pulse wave velocity in hypertensive postmenopausal women: comparison between a calcium channel blocker vs angiotensin receptor blocker regimen

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

7 January 2021

Effects of nisoldipine and lisinopril on left ventricular mass and function in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

7 January 2021

The relationship of electrocardiographic left ventricular hypertrophy to decreased serum potassium

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

7 January 2021

Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008170.PUB2

7 January 2021